CTLA4 and neoplasm: In addition, immune checkpoint molecules PD-1 (PDCD1), PD-L1 (CD274), and CTLA4 mediate tumor immune escape by suppressing the activity of immune cells and are known potential targets for RC immunotherapy (40).